{"pmid":32367471,"pmcid":"PMC7196627","title":"Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies.","text":["Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies.","J Thromb Thrombolysis","Porfidia, Angelo","Pola, Roberto","32367471"],"journal":"J Thromb Thrombolysis","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367471","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11239-020-02125-4","e_drugs":["Heparin"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496160497664,"score":9.490897,"similar":[{"pmid":32418066,"title":"Correction to: Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines.","text":["Correction to: Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines.","In the original version of the article, the article title was processed incorrectly. The correct article title is \"Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines\". This has been corrected with this erratum and the original article has also been updated to reflect the change in article title.","J Thromb Thrombolysis","Porfidia, Angelo","Pola, Roberto","32418066"],"abstract":["In the original version of the article, the article title was processed incorrectly. The correct article title is \"Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines\". This has been corrected with this erratum and the original article has also been updated to reflect the change in article title."],"journal":"J Thromb Thrombolysis","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418066","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11239-020-02139-y","link_erratum_for":"32367471","weight":0,"_version_":1667058206856183809,"score":129.29485},{"pmid":32311843,"title":"Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.","text":["Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.","In March 2020, the global healthcare system is overwhelmed by patients infected with SARS-CoV-2, which is the cause of the coronavirus pandemic (Covid-2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived.","Int J Lab Hematol","Beun, Robert","Kusadasi, Nuray","Sikma, Maaike","Westerink, Jan","Huisman, Albert","32311843"],"abstract":["In March 2020, the global healthcare system is overwhelmed by patients infected with SARS-CoV-2, which is the cause of the coronavirus pandemic (Covid-2019). A large number of these patients end up in the intensive care units (ICU) with critical illness requiring mechanical ventilation. One of the most important clinical features of the infection is a profound coagulopathy. In a recent cohort study 71% of patients who eventually died matched the ISTH criteria for disseminated intravascular coagulation (DIC), while this percentage was only 0.6% in patients who survived."],"journal":"Int J Lab Hematol","authors":["Beun, Robert","Kusadasi, Nuray","Sikma, Maaike","Westerink, Jan","Huisman, Albert"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311843","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ijlh.13230","e_drugs":["Heparin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138491200733186,"score":51.76505},{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Enoxaparin","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494470193152,"score":49.565296},{"pmid":32474397,"title":"Venous thromboembolism and COVID-19.","text":["Venous thromboembolism and COVID-19.","Respir Med Res","Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O","32474397"],"journal":"Respir Med Res","authors":["Bertoletti, L","Couturaud, F","Montani, D","Parent, F","Sanchez, O"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474397","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.resmer.2020.100759","keywords":["covid-19","coronavirus disease","pulmonary embolism","sars-cov-2","venous thromboembolic disease"],"topics":["Treatment"],"weight":1,"_version_":1668341932680544257,"score":49.555508},{"pmid":32392613,"title":"Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism.","text":["Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism.","Semin Thromb Hemost","Schulman, Sam","32392613"],"journal":"Semin Thromb Hemost","authors":["Schulman, Sam"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392613","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1055/s-0040-1710337","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666528580018896896,"score":48.57808}]}